“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management

Pietro Sollena, Simone Cappilli, Francesco Federico, Giovanni Schinzari, Giampaolo Tortora, Ketty Peris

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient’s immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte–associated protein 4, anti–programmed cell death protein 1 and its ligand inhibitors have been approved for advanced melanoma among other solid cancers. Although immunotherapy demonstrated a good safety profile, a new spectrum of multisystemic immune-related adverse events has been recently reported due to their use. Cutaneous reactions represent one of the leading adverse events, often reported in literature as “skin rash”, and rarely further characterized in distinct dermatologic entities. Herein we describe the distinctive cutaneous rashes occurring during immunotherapies for advanced melanoma, discussing implications in the treatment management.
Lingua originaleEnglish
pagine (da-a)1-8
Numero di pagine8
RivistaHUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume18
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • Advanced melanoma
  • CTLA-4 inhibitors
  • PD-1 inhibitors
  • cutaneous adverse events
  • immune checkpoint inhibitors
  • skin rash

Fingerprint

Entra nei temi di ricerca di '“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management'. Insieme formano una fingerprint unica.

Cita questo